Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 25;24(13):10602.
doi: 10.3390/ijms241310602.

Systemic Review of Clot Retraction Modulators

Affiliations

Systemic Review of Clot Retraction Modulators

Alaina Guilbeau et al. Int J Mol Sci. .

Abstract

Through a process termed clot retraction, platelets cause thrombi to shrink and become more stable. After platelets are activated via inside-out signaling, glycoprotein αIIbβIII binds to fibrinogen and initiates a cascade of intracellular signaling that ends in actin remodeling, which causes the platelet to change its shape. Clot retraction is also important for wound healing. Although the detailed molecular biology of clot retraction is only partially understood, various substances and physiological conditions modulate clot retraction. In this review, we describe some of the current literature pertaining to clot retraction modulators. In addition, we discuss compounds from Cudrania trucuspidata, Arctium lappa, and Panax ginseng that diminish clot retraction and have numerous other health benefits. Caffeic acid and diindolylmethane, both common in plants and vegetables, likewise reduce clot retraction, as do all-trans retinoic acid (a vitamin A derivative), two MAP4K inhibitors, and the chemotherapeutic drug Dasatinib. Conversely, the endogenous anticoagulant Protein S (PS) and the matricellular protein secreted modular calcium-binding protein 1 (SMOC1) both enhance clot retraction. Most studies aiming to identify mechanisms of clot retraction modulators have focused on the increased phosphorylation of vasodilator-stimulated phosphoprotein and inositol 1,4,5-triphosphate receptor I and the decreased phosphorylation of various phospholipases (e.g., phospholipase A2 (PLA2) and phosphatidylinositol-specific phospholipase Cγ2 (PLCγ2), c-Jun N-terminal kinase, and (PI3Ks). One study focused on the decreased phosphorylation of Sarcoma Family Kinases (SFK), and others have focused on increased cAMP levels and the downregulation of inflammatory markers such as thromboxanes, including thromboxane A2 (TXA2) and thromboxane B2 (TXB2); prostaglandin A2 (PGE2); reactive oxygen species (ROS); and cyclooxygenase (COX) enzyme activity. Additionally, pregnancy, fibrinolysis, and the autoimmune condition systemic lupus erythematosus all seem to affect, or at least have some relation with, clot retraction. All the clot retraction modulators need in-depth study to explain these effects.

Keywords: Protein S; actin remodeling; clot retraction; platelet activation; retraction modulators; thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Clot retraction signaling cascade. G-protein-coupled receptor binds thrombin, TXA2, ADP, epinephrine, and collagen, activating various phospholipases. Intracellular calcium and IP3 activate protein kinase C, which signals RAP-1 to bind an adaptor molecule. Talin and kindlin produce a conformational change in GP-αIIbβIII, increasing its affinity for fibrinogen. This process of inside-out signaling is shown against the grey background. Src is cleaved from the β3 tail of GP-αIIbβIII and, through various signaling pathways (not shown), forms a complex with tensin, vinculin, talin, and kindlin. Actin rearrangement occurs, which ultimately causes platelet contraction and stabilizes the clot. Outside-in signaling is shown against the white background.
Figure 2
Figure 2
PRISMA diagram of literature qualification process.

Similar articles

References

    1. Nurden A.T. Molecular basis of clot retraction and its role in wound healing. Thromb. Res. 2022 doi: 10.1016/j.thromres.2022.08.010. - DOI - PubMed
    1. Singh M., Akkaya S., Preuss M., Rademacher F., Tohidnezhad M., Kubo Y., Behrendt P., Weitkamp J.T., Wedel T., Lucius R., et al. Platelet-Released Growth Factors Influence Wound Healing-Associated Genes in Human Keratinocytes and Ex Vivo Skin Explants. Int. J. Mol. Sci. 2022;23:2827. doi: 10.3390/ijms23052827. - DOI - PMC - PubMed
    1. Samson A.L., Alwis I., Maclean J.A.A., Priyananda P., Hawkett B., Schoenwaelder S.M., Jackson S.P. Endogenous fibrinolysis facilitates clot retraction in vivo. Blood. 2017;130:2453–2462. doi: 10.1182/blood-2017-06-789032. - DOI - PubMed
    1. Jansen E.E., Hartmann M. Clot Retraction: Cellular Mechanisms and Inhibitors, Measuring Methods, and Clinical Implications. Biomedicines. 2021;9:1064. doi: 10.3390/biomedicines9081064. - DOI - PMC - PubMed
    1. Huang J., Li X., Shi X., Zhu M., Wang J., Huang S., Huang X., Wang H., Li L., Deng H., et al. Platelet integrin alphaIIbbeta3: Signal transduction, regulation, and its therapeutic targeting. J. Hematol. Oncol. 2019;12:26. doi: 10.1186/s13045-019-0709-6. - DOI - PMC - PubMed

Publication types